Purpose: To evaluate the potential role, safety, and efficacy of paclitaxel-eluting balloon angioplasty for treatment of recurrent carotid in-stent restenosis (ISR). Methods: Among 856 consecutive patients who underwent carotid artery stenting from May 2002 to January 2008, 41 patients had a significant ISR (>80% stenos's). Of these, 9 patients (7 women; mean age 78.1 +/- 5.6 years) had recurrent ISR despite multiple endovascular treatments (3.4 +/- 0.9 interventions) within a short period of time (2-5 months). These patients were treated with drug-eluting balloon (DEB) angioplasty for neointimal hyperplasia. Imaging (ultrasound or computed tomographic angiography) was performed at 1, 3, and 6 months and yearly thereafter. Results: Technical success was obtained in 100% of cases, with angiographic stenosis decreasing from 87% +/- 4% to 6% +/- 4% post treatment. Peak systolic velocity decreased significantly from 4.7 +/- 1.5 m/s to 0.6 +/- 0.3 m/s after the procedure. Over a mean follow-up of 36.6 +/- 2.7 months, ultrasound imaging indicated recurrent ISR in only 3 patients at 18, 25, and 32 months after DEB angioplasty, respectively. The target vessel revascularization rate was 33.3% at 36 months. No neurological or myocardial events were recorded during follow-up. One patient died at 3 months. Conclusion: DEB may have a potential role improving outcomes of those patients treated for early recurrent carotid ISR.

Gandini, R., DEL GIUDICE, C., DA ROS, V., Sallustio, F., Altobelli, S., D'Onofrio, A., et al. (2014). Long-term Results of Drug-Eluting Balloon Angioplasty for Treatment of Refractory Recurrent Carotid In-Stent Restenosis. JOURNAL OF ENDOVASCULAR THERAPY, 21(5), 671-677 [10.1583/14-4715MR.1].

Long-term Results of Drug-Eluting Balloon Angioplasty for Treatment of Refractory Recurrent Carotid In-Stent Restenosis

GANDINI, ROBERTO;DEL GIUDICE, COSTANTINO;DA ROS, VALERIO;STANZIONE, PAOLO;SIMONETTI, GIOVANNI MARIA EGISTO
2014-01-01

Abstract

Purpose: To evaluate the potential role, safety, and efficacy of paclitaxel-eluting balloon angioplasty for treatment of recurrent carotid in-stent restenosis (ISR). Methods: Among 856 consecutive patients who underwent carotid artery stenting from May 2002 to January 2008, 41 patients had a significant ISR (>80% stenos's). Of these, 9 patients (7 women; mean age 78.1 +/- 5.6 years) had recurrent ISR despite multiple endovascular treatments (3.4 +/- 0.9 interventions) within a short period of time (2-5 months). These patients were treated with drug-eluting balloon (DEB) angioplasty for neointimal hyperplasia. Imaging (ultrasound or computed tomographic angiography) was performed at 1, 3, and 6 months and yearly thereafter. Results: Technical success was obtained in 100% of cases, with angiographic stenosis decreasing from 87% +/- 4% to 6% +/- 4% post treatment. Peak systolic velocity decreased significantly from 4.7 +/- 1.5 m/s to 0.6 +/- 0.3 m/s after the procedure. Over a mean follow-up of 36.6 +/- 2.7 months, ultrasound imaging indicated recurrent ISR in only 3 patients at 18, 25, and 32 months after DEB angioplasty, respectively. The target vessel revascularization rate was 33.3% at 36 months. No neurological or myocardial events were recorded during follow-up. One patient died at 3 months. Conclusion: DEB may have a potential role improving outcomes of those patients treated for early recurrent carotid ISR.
2014
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/27 - NEUROCHIRURGIA
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
Gandini, R., DEL GIUDICE, C., DA ROS, V., Sallustio, F., Altobelli, S., D'Onofrio, A., et al. (2014). Long-term Results of Drug-Eluting Balloon Angioplasty for Treatment of Refractory Recurrent Carotid In-Stent Restenosis. JOURNAL OF ENDOVASCULAR THERAPY, 21(5), 671-677 [10.1583/14-4715MR.1].
Gandini, R; DEL GIUDICE, C; DA ROS, V; Sallustio, F; Altobelli, S; D'Onofrio, A; Abrignani, S; Vasili, E; Stanzione, P; Simonetti, Gme
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/99867
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 29
social impact